NCT03297502View on ClinicalTrials.gov

Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis

PHASE3CompletedINTERVENTIONAL
Enrollment

582

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Atopic Dermatitis
Interventions
DRUG

pimecrolimus cream 1%

DRUG

Elidel (pimecrolimus) cream 1%

DRUG

placebo

Sponsors
All Listed Sponsors
lead

Par Pharmaceutical, Inc.

INDUSTRY